Compare IQV & MKL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IQV | MKL |
|---|---|---|
| Founded | 1982 | 1930 |
| Country | United States | United States |
| Employees | 93000 | N/A |
| Industry | Biotechnology: Commercial Physical & Biological Resarch | Property-Casualty Insurers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.6B | 26.2B |
| IPO Year | 2013 | 1999 |
| Metric | IQV | MKL |
|---|---|---|
| Price | $168.96 | $1,957.02 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 16 | 1 |
| Target Price | $227.13 | ★ $2,100.00 |
| AVG Volume (30 Days) | ★ 1.2M | 46.0K |
| Earning Date | 05-05-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 4.67 | N/A |
| EPS | 7.84 | ★ 169.22 |
| Revenue | $9,739,000,000.00 | ★ $15,513,233,000.00 |
| Revenue This Year | $6.78 | N/A |
| Revenue Next Year | $5.88 | $2.22 |
| P/E Ratio | $22.03 | ★ $11.52 |
| Revenue Growth | ★ 41.60 | N/A |
| 52 Week Low | $134.65 | $1,698.99 |
| 52 Week High | $247.05 | $2,207.59 |
| Indicator | IQV | MKL |
|---|---|---|
| Relative Strength Index (RSI) | 44.69 | 54.48 |
| Support Level | $159.42 | $1,948.00 |
| Resistance Level | $170.89 | $1,999.37 |
| Average True Range (ATR) | 6.19 | 33.74 |
| MACD | 1.31 | 12.06 |
| Stochastic Oscillator | 36.04 | 84.55 |
Iqvia is a global leader in clinical research and technology solutions for the life science industry. Formed in 2016 from the merger of Quintiles and IMS Health, it combined clinical trial services with extensive healthcare data and analytics. Its reserach and development solutions segment provides outsourced clinical development services spanning drug discovery, trial design, patient recruitment, site management, clinical testing, real-world studies, and the regulatory approval process. Its commercial solutions segment helps companies optimize product commercialization through analytics, technology, and outsourced sales and medical services. Together, Iqvia supports customers across the life science industry, and it serves biopharmaceutical firms, providers, payers, and policymakers.
Markel's primary business is property and casualty insurance. The company focuses primarily on specialty lines, ranging from areas such as executive liability to commercial equine insurance. The acquisition of Alterra in 2013 added substantial reinsurance operations, which now account for a little over 10% of premiums. The company uses capital generated by its insurance operations to buy noninsurance operations in diverse areas, such as bakery equipment manufacturing and residential homebuilding.